Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA
Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA
editas medicine披露了RUBY试验中Reni-Cel在18例镰状细胞病患者中的安全性和有效性更新结果，此次试验由欧洲血液学会主办。
- All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion
- Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%.
- Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant
- 所有接受RUBY试验治疗的患者，在接受renizgamglogene autogedtemcel（reni-cel）输注后均未发生血管闭塞事件。
- 患者的总血红蛋白早期恢复，平均达到正常范围大于14 g/dL，并且胎儿血红蛋白水平迅速持续上升，远高于40%的水平。
- Reni-cel耐受性良好，并呈现出与用巴磺酸进行髓毒性调节和自体造血干细胞移植相一致的安全性。